photobyphm / Shutterstock.com
American pharmaceutical company Merck & Co. has secured a victory against its rival Pfizer in an inter partes review of a patent concerning Prevnar 13, the biggest-selling vaccine in the world.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck & Co., Pfizer, Prevnar 13, vaccine, pneumonia, patent invalidation, Patent Trial and Appeal Board, prior art
